Clinical trials: Atherosclerotic Vascular Diseases
Atherosclerotic Cardiovascular Disease
In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease
Study CKJX839B1FR01 in an In silico trial to predict the efficacy of Inclisiran therapy on major adverse cardiovascular events (MACE) and cardiovascular (CV) death in virtual patients with atherosclerotic cardiovascular disease…
- Trial name
- SIRIUS (NCT05974345)
- Testing
- Inclisiran sodium, Ezetimibe, Evolocumab
- Where
- France
- Volunteers
- 204,691 people
- Sponsor
- Novartis Pharmaceuticals
Peripheral Artery Disease
Mechanistic Clinical Trial of Colchicine in Patients With Peripheral Artery Disease
The goal of this mechanistic clinical trial is to test the effects of reducing inflammatory signaling in femoral artery atherosclerotic plaques.
- Trial name
- NCT06212271
- Testing
- Colchicine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Pennsylvania
Atherosclerotic Cardiovascular Disease
Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients
This study aims to confirm the effectiveness of ezetimibe add-on therapy on LDL-C levels compared to atorvastatin monotherapy, especially in very high-risk patients.
- Trial name
- BETTER (NCT05761444)
- Testing
- Atozet 10/40 mg or 10/80 mg, Lipitor 40 mg or 80 mg
- Where
- 7 sites in South Korea
- Volunteers
- 137 people
- Sponsor
- Organon and Co
Vertebral Artery Stenosis
Drug Eluting Stenting and Short Dual Antiplatelet Therapy for Preventing Recurrent Stroke in Vertebral Stenosis Registry Study
This is a prospective, multi-center, registry study exploring the duration of dual antiplatelet therapy (DAPT) after drug-eluting stent(DES) treatment of symptomatic vertebral artery atherosclerotic stenosis.
- Trial name
- M Short DAPT (NCT06683300)
- Testing
- DAPT for 3 months after vertebral artery stenting
- Where
- China
- Volunteers
- 520 people
- Sponsor
- Beijing Tiantan Hospital
Atherosclerosis
Natural History of Atherosclerosis
20 patients will be recruited. The aim of the study is to determine the natural progression of atherosclerotic disease.
- Trial name
- NCT00918541
- Where
- 3 sites in Switzerland
- Volunteers
- 30 people
- Sponsor
- University of Zurich
Cancer, Cardiotoxicity
BIOMARKER and IMAGING CHARACTERISATION of INFLAMMATORY ATHEROMA in PATIENTS RECEIVING IMMUNOTHERAPY and ANGIOGENESIS INHIBITORS
The advent of immunotherapy (immune checkpoint inhibitors [ICI]) has been an extremely important advancement for cancer treatment in recent decades.
- Conditions
- Cancer, Cardiotoxicity, Atherosclerotic Disease
- Trial name
- BIOCAPRI (NCT06597045)
- Testing
- PET/CT with 18-FDG
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- NHS Greater Glasgow and Clyde
Major Cardiovascular Event, Established Atherosclerotic Cardiovascular Disease
A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease
The primary objective of the study is to evaluate real-world effectiveness of treatment with Repatha® in combination with SOC, compared with SOC alone, on the risk for cardiovascular (CV) death, myocardial infarction (MI)…
- Trial name
- NCT06295679
- Where
- 90 sites in China
- Volunteers
- 7,000 people
- Sponsor
- Amgen
Vascular Diseases
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
The purpose of the study is to determine whether a p38 kinase inhibitor reduces inflammation in atherosclerotic plaque
- Trial name
- NCT00570752
- Testing
- BMS-582949, Atorvastatin, Statin
- Where
- 17 sites in United States
- Volunteers
- 72 people
- Sponsor
- Bristol-Myers Squibb
Myocardial Infarction
Prevalence and Long-term Impact of Non-atherosclerotic CAD
Despite a relatively high prevalence of non-atherosclerotic coronary artery disease (NACAD) among young women, the majority of these abnormalities were misdiagnosed in this population, and thus treatments were not targeted…
- Trial name
- PRYME (NCT01479140)
- Where
- Canada
- Volunteers
- 160 people
- Sponsor
- Cardiology Research UBC
Atherosclerotic Cardiovascular Disease
A Retrospective Cohort Study Evaluating Major Adverse Cardiovascular Events and Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events (OPTIMUS RISK - Italy)
This study will evaluate cardiovascular outcomes among individuals with clinically established atherosclerotic cardiovascular disease (ASCVD) who have not previously experienced a myocardial infarction (MI) or ischemic stroke.
- Trial name
- NCT07906132
- Where
- Italy
- Volunteers
- 93,000 people
- Sponsor
- Sanofi
Atherosclerotic Vascular Disease, Heterozygous Familial Hypercholesterolemia
Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE Study
This study aims to address several key questions regarding the use of inclisiran in real-world clinical practice in Spain.
- Trial name
- INSPIRE (NCT06958315)
- Testing
- Inclisiran
- Where
- 20 sites in Spain
- Volunteers
- 219 people
- Sponsor
- Novartis Pharmaceuticals
Intracranial Atherosclerosis, Intracranial Arterial Stenosis
EDAS Revascularization for Symptomatic Intracranial Atherosclerotic Steno-occlusive Disease
ERSIAS IIb is a multicenter randomized controlled trial, with a Phase IIb design, to find out whether encephaloduroarteriosynangiosis (EDAS), a type of indirect surgical revascularization of the brain, added to intensive medical…
- Conditions
- Intracranial Atherosclerosis, Intracranial Arterial Stenosis, Ischemic Stroke
- Trial name
- ERSIAS IIb (NCT07864649)
- Testing
- Encephaloduroarteriosynangiosis (EDAS), Intensive medical management
- Volunteers
- 170 people
- Sponsor
- Cedars-Sinai Medical Center
Cardiovascular Diseases, Atherosclerosis
Maternal and Offspring Outcomes in Pregnant Women With Pre-existing ASCVD
A growing body of evidence supports associations between cardiovascular health and adverse pregnancy outcome and between adverse pregnancy outcome and atherosclerotic cardiovascular disease and builds on the well-established…
- Conditions
- Cardiovascular Diseases, Atherosclerosis, Pregnancy Complications, Adverse Cardiac Event
- Trial name
- CVD_OBS (NCT06406998)
- Testing
- Pre-existing atherosclerotic cardiovascular disease
- Where
- South Korea
- Volunteers
- 5,461,222 people
- Sponsor
- Samsung Medical Center
Ischemic Stroke, Atherosclerosis of Artery
Efficacy of Probucol Combined with Statins Treatment for Ischemic Stroke
The goal of this clinical trial is to evaluate whether the combination of Probucol with statin therapy can reduce the risk of vascular events and improve atherosclerosis outcomes in adults with ischemic stroke and confirmed…
- Conditions
- Ischemic Stroke, Atherosclerosis of Artery, Lipid Disorder, Statin
- Trial name
- EPCIS (NCT06604117)
- Testing
- Statin, Probucol
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Xuanwu Hospital, Beijing
Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk
The purpose of this study is to see if bemedoic acid (ETC-1002) is effective versus placebo in patients with high cardiovascular risk and elevated LDL cholesterol not adequately controlled by their current therapy.
- Trial name
- CLEAR Wisdom (NCT02991118)
- Testing
- bempedoic acid
- Where
- 2 sites in United States
- Volunteers
- 779 people
- Sponsor
- Esperion Therapeutics, Inc.
Type 2 Diabetes Mellitus, Endothelial Dysfunction
Huangqi Gegen Decoction for Endothelial Function in Type 2 Diabetes at Very High ASCVD Risk
This clinical trial evaluates whether Huangqi Gegen Decoction can improve blood vessel function in adults with type 2 diabetes mellitus who are at very high risk of atherosclerotic cardiovascular disease and meet the traditional…
- Conditions
- Type 2 Diabetes Mellitus, Endothelial Dysfunction, Cardiovascular Risk
- Trial name
- NCT07775664
- Testing
- Huangqi Gegen Decoction Granules, Conventional Treatment
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Putuo Hospital, Shanghai University of Traditional Chinese Medicine
Carotid Stenosis, Carotid Artery Plaque
CARotid Mri of Atherosclerosis
In the entire world most people die from cardiovascular disease. Death is primarily from myocardial infarction (MI) and stroke which are most often caused by rupture of atherosclerotic plaques. Patients with high-grade, i.e.
- Conditions
- Carotid Stenosis, Carotid Artery Plaque, Carotid Atherosclerosis
- Trial name
- CARMA (NCT04835571)
- Testing
- Optimization of cardiovascular risk management
- Volunteers
- 52 people
- Sponsor
- Linkoeping University
Diabetes, Chronic Kidney Disease
The Alberta Vascular Risk Reduction Community Pharmacy Project: RxEACH
Cardiovascular disease (disease of the heart and blood vessels) is one of the leading causes of death in Canada. It also carries a financial burden on the Canadian economy with a yearly cost close to $21 billion divided between…
- Conditions
- Diabetes, Chronic Kidney Disease, Established Atherosclerotic Vascular Disease, Framingham Risk Score More Than 20 Percent
- Trial name
- RxEACH (NCT01979471)
- Testing
- Advanced Care
- Where
- Canada
- Volunteers
- 723 people
- Sponsor
- University of Alberta
Coronary Artery Disease
The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL)
The purpose of this study is to evaluate the safety and effectiveness of the PROMUS Element™ Everolimus-Eluting Coronary Stent System for the treatment of patients with up to 2 de novo atherosclerotic coronary artery lesions.
- Trial name
- PLATINUM LL (NCT01500434)
- Testing
- PROMUS Element Coronary Stent System, Aspirin, Thienopyridine
- Where
- 30 sites in United States, Australia and 5 more
- Volunteers
- 102 people
- Sponsor
- Boston Scientific Corporation
Stroke, Ischemic, Intracranial Atherosclerosis
Predictors of Intracranial Atherosclerotic Disease in Posterior Circulation: a Cohort Study
Early identification of intracranial atherosclerotic disease (ICAD) may impact the management of patients undergoing mechanical thrombectomy (MT).
- Conditions
- Stroke, Ischemic, Intracranial Atherosclerosis, Posterior Circulation Brain Infarction
- Trial name
- NCT06453252
- Testing
- we are aiming to develop a Scoring system based on certain variables derived from both groups
- Where
- 2 sites in United States, Egypt
- Volunteers
- 150 people
- Sponsor
- Sohag University